These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
496 related articles for article (PubMed ID: 29961278)
1. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia]. Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278 [No Abstract] [Full Text] [Related]
2. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia]. Song SQ; Zhang GN Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175 [TBL] [Abstract][Full Text] [Related]
3. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. Mao Y; Wan X; Lv W; Xie X Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633 [TBL] [Abstract][Full Text] [Related]
4. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709 [TBL] [Abstract][Full Text] [Related]
5. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia. Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033 [TBL] [Abstract][Full Text] [Related]
8. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Escobar PF; Lurain JR; Singh DK; Bozorgi K; Fishman DA Gynecol Oncol; 2003 Dec; 91(3):552-7. PubMed ID: 14675675 [TBL] [Abstract][Full Text] [Related]
9. Changes in the management of high-risk gestational trophoblastic neoplasia in the National Trophoblastic Disease Center of Hungary. Fülöp V; Szigetvári I; Szepesi J; Végh G; Berkowitz RS J Reprod Med; 2014; 59(5-6):227-34. PubMed ID: 24937962 [TBL] [Abstract][Full Text] [Related]
10. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years. Fülöp V; Szigetvári I; Szepesi J; Végh G; Singh M; Berkowitz RS J Reprod Med; 2012; 57(7-8):310-8. PubMed ID: 22838247 [TBL] [Abstract][Full Text] [Related]
12. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004 [TBL] [Abstract][Full Text] [Related]
13. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528 [TBL] [Abstract][Full Text] [Related]
14. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. Lurain JR; Schink JC J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816 [TBL] [Abstract][Full Text] [Related]
15. Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience. Al-Husaini H; Soudy H; Darwish A; Ahmed M; Eltigani A; Edesa W; Elhassan T; Omar A; Elghamry W; Al-Hashem H; Al-Hayli S; Madkhali I; Ahmad S; Al-Badawi IA Clin Transl Oncol; 2015 May; 17(5):409-15. PubMed ID: 25398721 [TBL] [Abstract][Full Text] [Related]
16. Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010. Agarwal R; Alifrangis C; Everard J; Savage PM; Short D; Tidy J; Fisher RA; Sebire NJ; Harvey R; Hancock BW; Coleman RE; Seckl MJ J Reprod Med; 2014; 59(1-2):7-12. PubMed ID: 24597279 [TBL] [Abstract][Full Text] [Related]
17. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. Lu WG; Ye F; Shen YM; Fu YF; Chen HZ; Wan XY; Xie X Int J Gynecol Cancer; 2008; 18(2):357-62. PubMed ID: 17711444 [TBL] [Abstract][Full Text] [Related]
18. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group. Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854 [TBL] [Abstract][Full Text] [Related]
19. Conservative Chemotherapy in Gestational Trophoblastic Disease: Experience With Etoposide, Methotrexate, and Dactinomycin Chemotherapy. Byun SW; Park TC; Bae SN Int J Gynecol Cancer; 2016 May; 26(4):790-5. PubMed ID: 27057813 [TBL] [Abstract][Full Text] [Related]
20. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia. Rattanaburi A; Boonyapipat S; Supasinth Y Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]